Robert Stanislaro News Today

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2024 -- ProQR Therapeutics NV. , a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™...

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 22, 2024 -- ProQR Therapeutics NV , a company dedicated to changing lives through transformative RNA therapies, today announced it will present new...

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkersAdditional data to be presented throughout 2024, including in vitro and in vivo data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Ca

Partnership focused on utilizing Axiomer™ to develop editing oligonucleotides targeting an underlying genetic variant that causes Rett syndromeCollaboration expands ProQR’s commitment to advance...

Economic and Political Uncertainty, Cybersecurity Incidents, Talent Scarcity and Declining Reimbursement Rates Identified as Biggest Risks Facing the Industry Technologies Such as Artificial...

Continued advancement of platform and initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascu...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicate...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 28, 2023 -- ProQR Therapeutics NV. , a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer® RNA...

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies today provided an update that its previously announced agreement to divest the Company’s late-stage ophthalmic assets to Laboratoires Théa S.A.S. (Théa) has been terminated. The completion of the transaction was conditional on Théa entering into employment agreements with a ...

Divestment of sepofarsen and ultevursen ophthalmic programs supports ProQR’s strategic focus on Axiomer® RNA editing platform technology and continued advancement of pipeline€129 M cash and cash equivalents as of June 30, 2023 providing runway into mid-2026 LEIDEN, Netherlands & CAMBRIDGE, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprieta...